Filipe Cabreiro's guest appearances

Filipe Cabreiro

Finding Genius Podcast

Health Psychology and Human Nature

Dario Valenzano

Ross Ulbricht

Lyn Ulbricht

Jameson Lopp

Marco Peereboom

Megan Ramos

Danny Flood

Abel James

Nir Eyal

Perry Marshall

Scott Young

Ben Goertzel

Steven Kotler

Ross Taylor

Scott Smith

OwlTail

Filipe Cabrerio researches how a host’s microbiome and physiology interact in the context of different conditions such as aging and metabolic syndrome while taking various medications. He shares some his lab’s research with listeners, explaining  What they found when studying colorectal cancer drugs and microbial metabolism, How metformin interacts with microbial physiologies to alter metabolic syndrome, and What future studies he hopes to instigate involving the vast genetic diversity in some of these microbes, even within the same species, and medical impactions for treatment.  Filipe Cabreiro holds a Sir Henry Dale Fellowship in the London Institute of Medical Sciences at the Imperial College of London. His lab works to understand how the microbiome interacts with a host’s physiology—how the microbes that one produces interact with others, especially when both are challenged by daily medications taken to deal with disease and in the conditions of aging. The lab recently made an important discovery in the context of cancer drugs: they found that classic drugs for colorectal cancer were modified by microbial metabolism that reduced or amplified the action of the drugs. Further, they found that certain components of food could change that response.  He also discusses a study on metformin, a drug taken for type 2 diabetes, and its interaction with the microbiome. They found that nutrients, the host’s microbiome, and the drug interact in an important way. Metformin makes selective pressures on certain gut microbes, which translates into longer lasting change associated with positive effects. They think metformin pushes for certain conditions that allow some healthful microbes to survive and also pushes strong metabolic change. The consequences of that change is the production of molecules such as fatty acids and others that can actively regulate the host’s physiology and metabolism. He explains the nature of this interaction and the significance in more detail along with challenges to these kinds of studies, further hypotheses, and future research he hopes to take on. For more, see his lab’s web page: cabreirolab.org. Available on Apple Podcasts: apple.co/2Os0myK

Filipe Cabrerio researches how a host’s microbiome and physiology interact in the context of different conditions such as <a href="https://www.findinggeniuspodcast.com/podcasts/gerontologist-berenice-benayoun-reconfigures-how-we-study-aging/" rel="noopener nofollow" target="_blank">aging</a> and metabolic syndrome while taking various medications. He shares some his lab’s research with listeners, explaining <ul> <li>What they found when studying colorectal cancer drugs and microbial metabolism,</li> <li>How metformin interacts with microbial physiologies to alter metabolic syndrome, and</li> <li>What future studies he hopes to instigate involving the vast genetic diversity in some of these microbes, even within the same species, and medical impactions for treatment.</li> </ul> Filipe Cabreiro holds a Sir Henry Dale Fellowship in the London Institute of Medical Sciences at the Imperial College of London. His lab works to understand how the microbiome interacts with a host’s physiology—how the microbes that one produces interact with others, especially when both are challenged by daily medications taken to deal with disease and in the conditions of <a href="https://www.findinggeniuspodcast.com/podcasts/gerontologist-berenice-benayoun-reconfigures-how-we-study-aging/" rel="noopener nofollow" target="_blank">aging</a>. The lab recently made an important discovery in the context of cancer drugs: they found that classic drugs for colorectal cancer were modified by microbial metabolism that reduced or amplified the action of the drugs. Further, they found that certain components of food could change that response.  He also discusses a study on metformin, a drug taken for type 2 diabetes, and its interaction with the microbiome. They found that nutrients, the host’s microbiome, and the drug interact in an important way. Metformin makes selective pressures on certain gut microbes, which translates into longer lasting change associated with positive effects. They think metformin pushes for certain conditions that allow some healthful microbes to survive and also pushes strong metabolic change. The consequences of that change is the production of molecules such as fatty acids and others that can actively regulate the host’s physiology and metabolism. He explains the nature of this interaction and the significance in more detail along with challenges to these kinds of studies, further hypotheses, and future research he hopes to take on. For more, see his lab’s web page: <a href="http://www.cabreirolab.org/" rel="noopener nofollow" target="_blank">cabreirolab.org</a>. Available on Apple Podcasts: <a href="https://t.co/lTCaaId6tO?amp=1" rel="nofollow" target="_blank">apple.co/2Os0myK</a>

Microbial Interactions with Medications: Filipe Cabreiro Talks Drugs and the Microbiome

How does our Microbiome affect our health and how long we live? How does drugs like Metformin and others affect us through the Microbiome? In today's conversation Filipe shares his views on this and a lot more.    Filipe Cabreiro is the Principal Investigator of the Cabreiro Lab which focus on how the Microbiome regulates the effect of Drugs and Diet on Healthspan and Lifespan.   Have a terrific day.

How does our Microbiome affect our health and how long we live? How does drugs like Metformin and others affect us through the Microbiome? In today's conversation Filipe shares his views on this and a lot more.  Filipe Cabreiro is the Principal Investigator of the Cabreiro Lab which focus on how the Microbiome regulates the effect of Drugs and Diet on Healthspan and Lifespan. Have a terrific day.

#47: The Microbiome and a Long Healthy Life - Ph.D. Filipe Cabreiro

Filipe Cabrerio researches how a host’s microbiome and physiology interact in the context of different conditions such as  aging and metabolic syndrome while taking various medications.  He shares some his lab’s research with listeners, explaining  What they found when studying colorectal cancer drugs and microbial metabolism, How metformin interacts with microbial physiologies to alter metabolic syndrome, and What future studies he hopes to instigate involving the vast genetic diversity in some of these microbes, even within the same species, and medical impactions for treatment.  Filipe Cabreiro holds a Sir Henry Dale Fellowship in the London Institute of Medical Sciences at the Imperial College of London. His lab works to understand how the microbiome interacts with a host’s physiology—how the microbes that one produces interact with others, especially when both are challenged by daily medications taken to deal with disease and in the conditions of  aging.  The lab recently made an important discovery in the context of cancer drugs: they found that classic drugs for colorectal cancer were modified by microbial metabolism that reduced or amplified the action of the drugs. Further, they found that certain components of food could change that response.  He also discusses a study on metformin, a drug taken for type 2 diabetes, and its interaction with the microbiome. They found that nutrients, the host’s microbiome, and the drug interact in an important way. Metformin makes selective pressures on certain gut microbes, which translates into longer lasting change associated with positive effects. They think metformin pushes for certain conditions that allow some healthful microbes to survive and also pushes strong metabolic change.  The consequences of that change is the production of molecules such as fatty acids and others that can actively regulate the host’s physiology and metabolism. He explains the nature of this interaction and the significance in more detail along with challenges to these kinds of studies, further hypotheses, and future research he hopes to take on. For more, see his lab’s web page: cabreirolab.org.  Available on Apple Podcasts: apple.co/2Os0myK 

Filipe Cabrerio researches how a host’s microbiome and physiology interact in the context of different conditions such as <a href="https://www.findinggeniuspodcast.com/podcasts/gerontologist-berenice-benayoun-reconfigures-how-we-study-aging/" rel="nofollow" target="_blank"> aging</a> and metabolic syndrome while taking various medications. He shares some his lab’s research with listeners, explaining <ul> <li>What they found when studying colorectal cancer drugs and microbial metabolism,</li> <li>How metformin interacts with microbial physiologies to alter metabolic syndrome, and</li> <li>What future studies he hopes to instigate involving the vast genetic diversity in some of these microbes, even within the same species, and medical impactions for treatment.</li> </ul> Filipe Cabreiro holds a Sir Henry Dale Fellowship in the London Institute of Medical Sciences at the Imperial College of London. His lab works to understand how the microbiome interacts with a host’s physiology—how the microbes that one produces interact with others, especially when both are challenged by daily medications taken to deal with disease and in the conditions of <a href="https://www.findinggeniuspodcast.com/podcasts/gerontologist-berenice-benayoun-reconfigures-how-we-study-aging/" rel="nofollow" target="_blank"> aging</a>. The lab recently made an important discovery in the context of cancer drugs: they found that classic drugs for colorectal cancer were modified by microbial metabolism that reduced or amplified the action of the drugs. Further, they found that certain components of food could change that response.  He also discusses a study on metformin, a drug taken for type 2 diabetes, and its interaction with the microbiome. They found that nutrients, the host’s microbiome, and the drug interact in an important way. Metformin makes selective pressures on certain gut microbes, which translates into longer lasting change associated with positive effects. They think metformin pushes for certain conditions that allow some healthful microbes to survive and also pushes strong metabolic change. The consequences of that change is the production of molecules such as fatty acids and others that can actively regulate the host’s physiology and metabolism. He explains the nature of this interaction and the significance in more detail along with challenges to these kinds of studies, further hypotheses, and future research he hopes to take on. For more, see his lab’s web page: <a href="http://www.cabreirolab.org/" rel="nofollow" target="_blank">cabreirolab.org</a>. Available on Apple Podcasts: <a href="https://podcasts.apple.com/us/podcast/id1169016854" rel="nofollow" target="_blank">apple.co/2Os0myK</a>